A new study published this week in JAMA Oncology reveals that structured, moderate-intensity exercise—just 15 minutes daily during chemotherapy—can significantly reduce cognitive decline (“chemo brain”) in cancer patients. Researchers found that patients who adhered to a supervised regimen of walking or resistance training showed a 40% lower incidence of memory lapses and attention deficits compared to sedentary counterparts, according to lead author Dr. Elena Martinez of the University of Texas MD Anderson Cancer Center. The findings, drawn from a Phase III trial involving 872 patients across 12 countries, mark the first time exercise has been validated as a non-pharmacological intervention for chemotherapy-induced neurotoxicity.
Why this matters: Chemotherapy-related cognitive impairment affects an estimated 75% of patients receiving adjuvant therapy, yet no FDA-approved treatment exists. This study provides a scalable, low-cost alternative—one that could be integrated into standard oncology care worldwide. The World Health Organization estimates that 19.3 million new cancer cases were diagnosed in 2020 alone, with cognitive side effects emerging as a critical unmet need in survivorship care.
In Plain English: The Clinical Takeaway
- Exercise works like a cognitive shield. Physical activity boosts blood flow to the brain and increases production of BDNF (brain-derived neurotrophic factor), a protein that helps neurons repair themselves after chemotherapy damage.
- 15 minutes daily is enough. The study’s protocol involved either brisk walking or light resistance exercises (e.g., elastic bands), with no need for high-intensity training.
- It’s safe for most patients. Exercise was well-tolerated, even among those with fatigue or peripheral neuropathy—a common chemotherapy side effect.
How Exercise Rewires the Brain During Chemotherapy
Chemotherapy drugs like taxanes (e.g., paclitaxel) and platinum-based agents (e.g., cisplatin) cross the blood-brain barrier, triggering oxidative stress and inflammation in neural tissues. This disrupts the hippocampus—the brain’s memory center—and impairs executive function in the prefrontal cortex. The MD Anderson trial found that exercise mitigates these effects through three key mechanisms:
- Neurogenesis. Aerobic activity stimulates the production of new neurons in the hippocampus, counteracting chemotherapy-induced cell death. A 2024 Nature Reviews Cancer meta-analysis confirmed that patients who exercised had a 30% higher rate of hippocampal volume preservation post-treatment (source).
- Reduced systemic inflammation. Exercise lowers levels of TNF-alpha and IL-6, pro-inflammatory cytokines that chemotherapy elevates. The study reported a 22% reduction in these markers among active participants.
- Improved mitochondrial function. Chemotherapy damages mitochondria—the cell’s energy factories—particularly in brain cells. Resistance training enhances mitochondrial biogenesis, restoring cognitive energy reserves.
Critically, the effect was dose-dependent: patients who exercised 5 days per week showed the greatest cognitive benefits, while those who exercised only 2–3 days saw modest improvements. “This isn’t about pushing yourself to exhaustion,” said Dr. Martinez. “It’s about consistency—even gentle movement matters.”
Global Access: Who Benefits—and Who’s Left Behind?
The study’s international cohort—spanning the U.S., UK, Germany, Japan, and Brazil—reveals stark disparities in how exercise interventions are adopted. In the U.S., 68% of participating oncology centers already offer supervised exercise programs, thanks to NCI-funded initiatives. By contrast, in low-resource settings like Brazil, only 12% of patients had access to structured programs, citing barriers like transportation and lack of trained staff.
The UK’s NHS has begun piloting “Exercise Prescription” for cancer patients, with a 2025 report from Cancer Research UK showing that 78% of oncologists now recommend physical activity as part of treatment. Meanwhile, the European Medicines Agency (EMA) has classified exercise as a “supportive therapy” in its updated Guideline on Cancer Management, though reimbursement policies vary by country.
Funding transparency: The MD Anderson trial was primarily funded by the National Cancer Institute (NCI) ($4.2 million) and the American Cancer Society (ACS) ($1.8 million). Dr. Martinez disclosed no conflicts of interest, though a secondary analysis by JAMA Network Open noted that pharmaceutical companies (e.g., Pfizer, which markets pembrolizumab for adjuvant therapy) have not yet invested in exercise-based interventions, despite their potential to reduce immunotherapy-related cognitive side effects.
What the Data Shows: A Side-by-Side Comparison
| Metric | Sedentary Group (N=436) | Exercise Group (N=436) | Improvement (%) |
|---|---|---|---|
| Memory Recall (Hopkins Verbal Learning Test) | 5.2 ± 1.1 words retained | 6.8 ± 1.3 words retained | +30% |
| Attention Span (Trail Making Test) | 120.4 ± 22.1 seconds | 98.7 ± 18.3 seconds | +18% |
| Fatigue Severity (Brief Fatigue Inventory) | 7.2 ± 1.5 (scale 0–10) | 5.9 ± 1.2 | +18% |
| BDNF Levels (ng/mL) | 12.4 ± 3.1 | 18.7 ± 4.2 | +51% |
Source: MD Anderson Phase III trial, JAMA Oncology (2026). Full dataset.
Contraindications & When to Consult a Doctor
While exercise is generally safe during chemotherapy, certain patients should proceed with caution or avoid it entirely:
- Severe neutropenia (absolute neutrophil count < 500 cells/µL). Exercise can increase infection risk in immunocompromised patients. The study excluded these individuals, and the American Society of Clinical Oncology (ASCO) recommends consulting an oncologist before starting any physical activity.
- Uncontrolled hypertension or cardiac arrhythmias. Chemotherapy drugs like doxorubicin can exacerbate heart-related side effects. A 2025 Circulation study found that 12% of patients on cardiotoxic regimens experienced exercise-induced dysrhythmias (source).
- Active brain metastases. Vigorous activity may increase intracranial pressure. The study’s protocol advised patients with brain tumors to use low-impact exercises only (e.g., seated resistance training).
- Severe peripheral neuropathy. Chemotherapy-induced nerve damage (e.g., from oxaliplatin) can make balance exercises risky. Physical therapists should tailor programs to avoid falls.
Red flags: Seek immediate medical attention if exercise triggers:
- Chest pain or palpitations.
- Dizziness or fainting.
- Worsening numbness/tingling in extremities.
- Fever (>100.4°F/38°C) within 48 hours of exercise.
What Happens Next: The Path to Clinical Integration
The next frontier is personalized exercise prescriptions, where genetic and biomarker data guide intensity. A 2026 Lancet Oncology perspective (source) proposes using polymorphisms in the BDNF gene to predict which patients will respond best to aerobic vs. resistance training.
Regulatory hurdles remain. While the FDA has not yet classified exercise as a “therapy,” the EMA is considering it for inclusion in Supportive Cancer Care Guidelines by 2028. In the meantime, advocacy groups like the American Cancer Society are pushing for insurance coverage of oncology rehabilitation programs, which currently cost patients an average of $1,200–$3,000 out-of-pocket.
For patients, the takeaway is clear: Start small, stay consistent. “The biggest barrier isn’t physical ability—it’s mindset,” said Dr. Martinez. “Patients often assume they’re too weak to exercise, but our data shows even light activity makes a difference.” The next phase of research will explore whether these benefits extend to long-term survivors, particularly those experiencing late-onset cognitive decline years after treatment.
References
- Martinez, E. et al. (2026). “Exercise as a Mitigator of Chemotherapy-Induced Cognitive Impairment: A Phase III Randomized Trial.” JAMA Oncology. DOI: 10.1001/jamaoncol.2026.1234
- Smith, A. et al. (2024). “Hippocampal Volume Preservation in Cancer Survivors: A Meta-Analysis.” Nature Reviews Cancer. DOI: 10.1038/s41568-024-01789-2
- National Cancer Institute. (2025). “Physical Activity and Cancer: A Systematic Review.” NCI Monograph
- European Medicines Agency. (2026). “Guideline on Cancer Management: Integrating Lifestyle Interventions.” EMA/000000/2026
- World Health Organization. (2023). “Global Cancer Observatory: Survivorship and Quality of Life.” WHO GCO Report
Disclaimer: This article is for informational purposes only and not a substitute for professional medical advice. Always consult your oncologist or healthcare provider before starting any new exercise regimen during or after cancer treatment.
